During this cycle, CD103+/CD141+ DCs bearing CCR7 play a key role in delivering tumor antigens to TDLNs; furthermore, the paucity of CCR7 can lead to blocked T-cell initiation with tumor growth, and the loss of activated CD103+ DCs in tumors will reduce the efficacy of checkpoint blockade [38, 39]. The gene discussed is CCR7; the disease is neoplasm.